DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-01-08

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00017576

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-11

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00074178

Locations: 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Phase 2

Terminated

Conditions: Drug/Agent Toxicity by Tissue/Organ
Brain and Central Nervous System Tumors
Lymphoma
Thrombocytopenia

Interventions: Drug: Rituxan
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Etoposide phosphate
Drug: Carboplatin
Drug: Sodium thiosulfate
Drug: Neupogen
Drug: Neulasta
Drug: Cytarabine

First Posted Date: 2003-12-11

Last Posted Date: 2023-07-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00074165

Locations: 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-11

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00074191

Locations: 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer
Menopausal Symptoms
Osteoporosis

First Posted Date: 2003-08-06

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00031811

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-28

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00053248

Locations: 🇺🇸
UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: imatinib mesylate

First Posted Date: 2003-01-27

Last Posted Date: 2016-01-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00022490

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Terminated

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2012-08-20

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00015847

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: mitoxantrone hydrochloride
Procedure: conventional surgery

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 57

Registration Number: NCT00017563

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy